VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CLBCore Laboratories N.V.
$11.02$507M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCLBCash Flow

Core Laboratories N.V. (CLB) Cash Flow Statement

30Y historyFree accessUpdated daily

Cash flow generation is highly unstable, as evidenced by a volatile operating cash flow to net income ratio of -5.03 in 2026Q1 and a commitment to $4.0 million in share repurchases despite reporting a net loss.

CLB Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations35.1M37.18M56.39M24.79M24.96M36.58M57.87M89.53M111.83M124.27M131.89M219.1M303.45M298.14M237.2M204.13M205.83M181.87M155.21M125.69M120.31M74.78M54.2M60.88M40.98M28.32M7.27M4.5M6.6M-1.9M8.8M
Operating CF Margin %-7.06%10.76%4.86%5.1%7.78%11.88%13.4%15.96%18.83%22.18%27.47%27.96%27.77%24.18%22.49%25.9%26.15%19.88%18.75%20.9%15.47%12.68%15.01%11.24%7.52%2.16%1.48%2.31%-0.88%8.35%
Operating CF Growth %-151.31%-34.07%127.47%-0.67%-31.78%-36.79%-35.36%-19.94%-10.01%-5.77%-39.81%-27.8%1.78%25.69%16.2%-0.83%13.17%17.18%23.48%4.48%60.88%37.98%-10.98%48.54%44.72%289.68%61.49%-31.82%447.37%-121.59%14.29%
Net Income31.17M31.8M32.15M37.02M19.66M20.22M-96.92M93.71M79.79M83.1M63.86M114.93M258.63M243.19M216.61M184.64M145.4M114.09M143.6M121.11M82.66M31.72M12.29M18.7M-9.06M20.63M19.15M3.4M20M15.4M7.7M
Depreciation & Amortization14.7M14.65M14.95M15.78M17.16M18.52M20.87M22.61M23.09M24.94M26.87M27.46M26.7M25.47M22.92M23.3M23.27M24.33M21.77M19.48M17.69M17.06M17.4M23.54M20.1M22.54M19.22M18.7M16.5M11M4.6M
Stock-Based Compensation7.47M7.14M3.75M13.97M7.76M19.09M7.39M20.88M34.19M22.94M22.08M21.28M20.47M20.53M18.38M17.16M8.52M5.9M4.74M000000000000
Deferred Taxes-6.6M-4.74M674K-10.81M433K6.01M-12.22M-36.34M1.83M9.02M-14.38M-107K4.68M6.79M3.6M-6.55M-10.13M25.64M-1.36M6.1M8.06M81K-2.74M-1.65M-1.76M-17K-911K-1.8M-5.2M00
Other Non-Cash Items-8.29M-6.11M-3.03M-2.41M4.97M-3.01M132.81M-478K-17.18M-6.32M-1.74M8.54M-359K-4.39M-894K6.59M16.59M13.9M-1.21M-3.79M5.06M17.85M23.84M8.18M22.66M-153K-627K-700K4.2M-200K600K
Working Capital Changes-3.67M-5.57M7.88M-28.77M-25.02M-24.25M5.94M-10.84M-9.89M-9.4M35.2M47M-6.67M6.55M-23.42M-21.02M22.19M-1.98M-12.34M-17.2M6.83M8.07M3.4M12.12M9.04M-14.68M-29.57M-15.1M-28.9M-28.1M-4.1M
Change in Receivables5.72M-4.95M-3.61M-2.62M-10.08M-13.52M46.42M-3.19M2.27M-18.57M31.58M49.26M3.49M-16.31M-16.66M-12.08M-22.41M9.99M-5.03M000000000000
Change in Inventory-475.66K2.64M9.37M-12.98M-14.86M-4.55M1.47M-3.89M-10.4M446K6.22M3.05M2.89M1.29M3.22M-16.03M-2.44M1.85M-5.58M1.05M-4.14M-2.99M-904K4.09M6.58M-2.19M-9.3M-12M-2.8M-1.3M-900K
Change in Payables565.34K477K519K-12.88M15.37M6.57M-12.84M-3.76M-1.75M8.72M-1.04M-13.35M-3.02M-6.34M-3.67M11.97M11.7M-17.53M2.8M000000000000
Cash from Investing-6.57M-2.23M-6.39M-6.65M-3.86M-10.22M7.85M-5.68M-70.64M-20.56M-14.72M-39.65M-42.07M-43.2M-34M-52.02M-38.58M-18.54M-41.11M-19.98M-23.59M-16.36M5.94M-36.13M-25.34M-40.84M-28.41M10M-18M-92.1M-10.4M
Capital Expenditures-11.32M0-13.03M-10.58M-10.22M-13.54M-11.88M-22.27M-21.74M-18.77M-11.7M-24.26M-37.44M-38.95M-32.8M-30.15M-27.8M-17.53M-31.3M-24.14M-24.68M-19.09M-10.89M-22.97M-19.14M-29.05M-32.84M-19.1M-27M-15.3M-6.3M
CapEx % of Revenue2.16%2.77%2.49%2.08%2.09%2.88%2.44%3.33%3.1%2.85%1.97%3.04%3.45%3.63%3.34%3.32%3.5%2.52%4.01%3.6%4.29%3.95%2.55%5.66%5.25%7.71%9.77%6.29%9.43%7.12%5.98%
Acquisitions-210.07K-1.24M00240K873K1.51M2.98M-47.31M0-1.24M-13.77M-1.2M-98K-878K-18.82M-9M-11.54M-11.54M-7.34M00-1.78M-12.97M-7.99M-12.81M00000
Investments-------------------------------
Other Investing4.96M-994K6.63M3.93M6.12M-11.82M18.22M-6.77M-23.24M-18.45M-10.96M-22.94M-36.56M-37.91M-29.94M-33.2M-29.58M-16.95M-29.57M11.51M1.09M2.73M18.61M-183K1.79M1.01M4.43M29.1M9M-76.8M-4.3M
Cash from Financing-27.4M-31.25M-45.96M-18.45M-23.38M-22.46M-63.01M-85.87M-42.47M-104.08M-124.9M-180.3M-263.12M-249.08M-213.3M-256.66M-214.42M-18.43M-103.58M-134.33M-56.23M-60.7M-60.33M-22.88M-15.22M14.46M15.08M-4.5M6.9M101.6M-400K
Debt Issued (Net)-13.02M-16.71M-38M-9M-15M-71M-46M15M64M10M-217.24M75.34M88.84M32.95M8.65M68.86M-82.25M0-56.4M263K210.5M-26.98M-17.51M35.86M-7.27M11.15M11.74M-5.11M9.62M52.9M-700K
Equity Issued (Net)-10.53M-12.43M-5.31M-2.2M-3.9M51.74M-2.79M-3.31M-7.45M-16.91M190.04M-159.71M-264.37M-227.22M-175.73M-61.83M-92.14M-9.39M-31.74M-163.37M-179.74M-33.23M-42.82M-56.43M-8.4M2.96M3.14M2M1.77M50.2M0
Dividends Paid-1.89M-1.87M-1.88M-1.87M-1.85M-1.83M-12.45M-97.57M-97.25M-97.14M-95.14M-94.23M-89.09M-58.64M-52.95M-46.03M-39.97M-26.68M-27.64M000000000000
Share Repurchases-14.52M-12.43M-5.31M-2.2M-3.9M-8.26M-2.79M-3.31M-7.45M-16.91M-7.16M-159.71M-264.37M-227.22M-175.73M-61.83M-92.49M-9.39M-31.74M-181.81M-251.09M-41.45M-51.31M-57.97M-9.01M000000
Other Financing-1.96M-254K-775K-5.38M-2.62M-1.37M-1.77M8K-1.77M-26K-2.55M-1.7M1.5M3.83M6.72M-217.67M-233K17.64M12.2M28.78M-86.99M-488K0-2.3M421K355K468K-1.47M151K00
Net Change in Cash857K3.69M4.04M-308K-2.27M3.9M2.71M-2.02M-1.28M-364K-7.73M-856K-1.74M5.86M-10.11M-104.55M-47.16M144.91M10.52M-28.61M40.48M-2.29M-195K1.88M420K1.94M-6.07M9.9M-4.5M7.6M-2M
Free Cash Flow23.83M22.59M43.36M14.21M14.74M23.04M45.99M67.26M90.09M105.5M120.18M194.84M266.01M259.19M204.4M173.98M178.03M164.34M123.9M101.55M95.62M55.68M43.31M37.91M21.85M-727K-25.58M-14.6M-20.4M-17.2M2.5M
FCF Margin %4.54%4.29%8.28%2.79%3.01%4.9%9.44%10.07%12.85%15.99%20.21%24.43%24.51%24.14%20.83%19.17%22.4%23.63%15.87%15.14%16.61%11.52%10.13%9.34%5.99%-0.19%-7.61%-4.81%-7.13%-8%2.37%
FCF Growth %-45.8%-47.91%205.14%-3.6%-36.02%-49.9%-31.62%-25.34%-14.61%-12.22%-38.32%-26.75%2.63%26.8%17.49%-2.28%8.33%32.64%22.01%6.2%71.73%28.57%14.25%73.5%3105.09%97.16%-75.19%28.43%-18.6%-788%-53.7%
FCF per Share0.520.490.910.300.310.491.021.512.032.382.724.545.965.644.303.603.693.522.592.081.780.990.750.610.33-0.01-0.38-0.23-0.34-0.330.06
FCF Conversion (FCF/Net Income)0.76x1.17x1.80x0.68x1.28x1.85x-0.59x0.88x1.41x1.49x2.06x1.91x1.18x1.23x1.10x1.11x1.42x1.60x1.08x1.04x1.46x2.40x4.41x3.26x-4.52x1.37x0.38x1.32x0.33x-0.12x1.14x
Interest Paid2.49M010.86M11.2M9.3M10.48M11.67M13.63M11.5M10.53M11.25M12.31M10.27M8.87M7.35M2.31M566K597K763K000000000000
Taxes Paid4.66M028.44M29.07M28.16M18.13M21.32M13.8M31.93M24.31M12.18M35.52M79.64M57M85.66M74.72M57.26M41.7M56.08M000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Cyclical Revenue Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Lacks Cash Alignment

As reported in financial statements, Core Laboratories' operating cash flow to net income ratio reached a volatile -5.03 in 2026Q1, indicating a significant disconnect between accounting profits and actual cash generation that warrants further investigation into the company's underlying accrual quality and operational efficiency.

The frequent divergence between net income and operating cash flow suggests that non-cash charges and working capital fluctuations are heavily influencing reported earnings. Investors should monitor whether this pattern of negative conversion persists, as it may indicate that the company's reported profitability is not translating into sustainable liquidity.

Free Cash Flow Margin Volatility

Based on the provided quarterly data, Core Laboratories' free cash flow margins have fluctuated significantly, ranging from a low of 1.9% in 2024Q1 to a peak of 13.1% in 2023Q4, highlighting the inherent instability in the firm's ability to convert revenue into discretionary cash.

The inconsistency in free cash flow generation appears to be driven by the cyclical nature of the Production Enhancement segment. This variability suggests that the company's cash flow trajectory remains highly sensitive to short-term market conditions rather than reflecting a steady, predictable growth profile.

Capital Intensity Remains Relatively Low

According to recent SEC filings, Core Laboratories maintained a capital expenditure to revenue ratio averaging approximately 2.6% over the last ten quarters, which suggests an asset-light operational model that requires minimal reinvestment to sustain its current specialized laboratory service offerings.

While the low capital intensity supports the company's asset-light narrative, it also implies that the firm may be under-investing in new technology or laboratory capacity. Analysts should consider whether this level of spending is sufficient to maintain a competitive edge against larger, better-capitalized peers in the long term.

Working Capital Swings Obscure Performance

As indicated by the reported figures, working capital changes have been a major source of cash flow volatility, with swings ranging from a $9.7 million inflow in 2024Q4 to a $9.9 million outflow in 2024Q1, complicating the assessment of core operational cash generation.

These erratic movements in working capital suggest that the company's collection cycles and inventory management are highly susceptible to project-based revenue recognition and client payment delays. This volatility may mask the true underlying cash-generating capability of the business during periods of shifting demand.

Capital Allocation Strategy Under Pressure

Based on the provided data, Core Laboratories has consistently utilized cash for dividends and share repurchases, with buybacks totaling $4.0 million in 2026Q1, even as net income turned negative, suggesting a commitment to shareholder returns that may be straining the company's liquidity position.

The decision to continue returning capital during periods of earnings weakness appears to prioritize shareholder sentiment over balance sheet preservation. Investors should monitor whether this allocation strategy remains sustainable if the current cyclical downturn in the energy services sector continues to impact cash flow.

CLB — Frequently Asked Questions

Quick answers to the most common questions about buying CLB stock.

How much cash does Core Laboratories N.V. (CLB) generate from operations?

Core Laboratories N.V. (CLB) generated $37.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Core Laboratories N.V.'s free cash flow?

Core Laboratories N.V. (CLB) generated $22.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Core Laboratories N.V.'s capital expenditure (CapEx)?

Core Laboratories N.V. (CLB) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Core Laboratories N.V. distribute cash to shareholders?

In 2025, Core Laboratories N.V. (CLB) returned $1.9M to shareholders via cash dividends and spent $12.4M on share repurchases. This shows the company's commitment to returning capital to its equity investors.